1859053-21-6

Basic information

• Product Name: Rucaparib Camsylate
• Synonyms: Rucaparib Camsylate;8‐Fluoro‐2‐(4‐methylaminomethyl‐phenyl)‐1,3,4,5‐tetrahydro‐azepino[5,4,3‐cd] indol‐6‐one (S)‐camphorsulfonate Salt;Rucaparib Camphosulfonate
• CAS NO: 1859053-21-6
• Molecular Formula: C29H34FN3O5S
• Molecular Weight: 555.6607632
• EINECS: -0
• Mol File: 1859053-21-6.mol
• Article Data: 0

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Rucaparib Camsylate(CAS DataBase Reference)
• NIST Chemistry Reference: Rucaparib Camsylate(1859053-21-6)
• EPA Substance Registry System: Rucaparib Camsylate(1859053-21-6)

Safety Data

• Hazardous Substances Data: 1859053-21-6(Hazardous Substances Data)

Usage

Description

Rucaparib Camsylate is a novel DNA repair enzyme poly-ADP ribose polymerase-1 (PARP-1) inhibitor, which plays a crucial role in the treatment of various types of cancer by targeting and inhibiting the PARP-1 enzyme, thereby disrupting the cancer cells' ability to repair their DNA and leading to cell death.

Uses

Used in Pharmaceutical Industry:
Rucaparib Camsylate is used as an anticancer agent for the treatment of various types of cancer, including ovarian, breast, pancreatic, and prostate cancers. It works by inhibiting the PARP-1 enzyme, which is involved in the repair of DNA damage in cancer cells, leading to the accumulation of DNA damage and ultimately cell death.
Used in Research and Development:
Rucaparib Camsylate is also used as a research tool in the field of oncology, where it helps scientists understand the role of PARP-1 in cancer development and progression. It is employed in preclinical studies to investigate the potential of PARP-1 inhibitors as a therapeutic strategy for various types of cancer.
Used in Drug Development:
Rucaparib Camsylate serves as a lead compound in the development of new PARP-1 inhibitors with improved potency, selectivity, and pharmacokinetic properties. Researchers are working on optimizing the structure of Rucaparib Camsylate to enhance its efficacy and safety profile, with the aim of developing more effective cancer treatments.